NF1 inactivation revs up Ras in adult acute myelogenous leukemia.
Mutations in the Ras pathway are common in myeloid malignancies. NF1, a tumor suppressor and negative regulator of Ras, is inactivated in a subset of adult acute myelogenous leukemia (AML) cases. Loss of NF1 function sensitizes cells to inhibition of mammalian target of rapamycin (mTOR), a downstream effector of Ras activation, highlighting a potential therapeutic opportunity for some AML patients.
Mullally
Ann
A
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ebert
Benjamin L
BL
D000328:Adult; D015870:Gene Expression; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D020868:Gene Silencing; D016514:Genes, Neurofibromatosis 1; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics*; D015398:Signal Transduction / Q000235:genetics*; D018631:ras Proteins / Q000096:biosynthesis*
D018631:ras Proteins